No Data
The Past Three Years for Betta Pharmaceuticals (SZSE:300558) Investors Has Not Been Profitable
Betta Pharmaceuticals (300558.SZ): Currently, the Engineering & Construction of the DreamWorks Phase II and Shengzhou base has been completed.
Gelonghui reported on December 20 that Betta Pharmaceuticals (300558.SZ) stated on the investor interaction platform that the Engineering & Construction of the second phase of the DreamWorks and the Shengzhou base has been completed. The subsequent Operating usage plan is currently being promoted, and major milestones regarding the project progress should be closely followed in the company's information disclosure and public announcements through WeChat official accounts.
Betta Pharmaceuticals (300558.SZ) subsidiary Xcovery has received FDA approval in the USA for the sale of its ensartinib hydrochloride capsules.
Betta Pharmaceuticals (300558.SZ) announces that the USA Food and Drug Administration (referred to as "USA FDA")...
FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Zhongtai: The implementation of the tenth batch of centralized procurement is expected to accelerate the clearance of generic drugs. Commercial insurance is an important incremental logic in the pharmaceutical Sector.
It is recommended to keep a close eye on the progress and implementation of commercial insurance, as improvements in the payment sector are expected to bring about a significant market trend in the Pharmaceutical Sector, with opportunities for recovery and reversal in hospital pharmaceuticals, diagnostics, and Medical Devices.
Betta Pharmaceuticals (300558.SZ) granted 1.6898 million restricted stocks to 171 incentive recipients.
betta pharmaceuticals (300558.SZ) announced that the company approved the "Regarding the Granting of 2023 Incentives to Incentive Objects...
Betta Pharmaceuticals' (SZSE:300558) Earnings Have Declined Over Three Years, Contributing to Shareholders 62% Loss
